Pfizer calls for action to attract global life sciences investment in Australia
Posted: 13 August 2024 Pfizer Australia is urging policy change to make Australia more attractive for global life sciences investment. In its new report, ‘Breakthrough Nation’, launched at the beginning of National Science Week (10-18 August), Pfizer highlights…
Clear line of sight to solving irreversible vision loss
Posted: 13 August 2024 One in 2 people with glaucoma doesn’t know they have it. And, shockingly, half of these people have had an eye test in the past year. Yet good 3-dimensional scanning technology, already used by…
$3.7 million funding boost for infection prevention and control in aged care
Posted: 13 August 2024 The Albanese Government is investing more than $3.7 million in funding towards targeted research into improving infection prevention and control (IPC) in aged care homes as part of its commitment to delivering high quality…
Amplia Receives R&D Tax Rebate Totalling $3.2 Million
Posted: 13 August 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to advise that it has received a Research and Development (R&D) Tax Incentive refund of $3,177,718 for the 2023/2024 financial year. The refund…
One More Patient Shows Sustained Reduction in Tumour Size in Pancreatic Cancer Trial
Posted: 8 August 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that a fourth patient enrolled in the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer…
Granting of Key Chemical Form Patent in Europe and Japan
Posted: 8 August 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce the granting of a key patent in Europe and Japan. The patent, entitled A salt and crystal form of a FAK…
Participate in Alzheimer’s research
Posted: 8 August 2024 We are seeking individuals aged 50-85 years who have been diagnosed with Alzheimer’s disease to participate in a clinical trial of Transcranial Magnetic Stimulation (TMS) TMS is a well-tolerated non-invasive brain stimulation technique that…
Unicorns of Australian innovation revealed in new Phase III Podcast
Posted: 8 August 2024 Experienced business journalists and podcasters, Rachel Williamson and Charis Palmer, have joined forces to fill a significant gap in Australia’s media landscape for health innovators, today launching a new podcast called Phase III. The…
First recipients of the Burnext accelerator program
Posted: 8 August 2024 Two exciting projects are being funded through Burnet Institute’s Burnext accelerator program, designed to enhance research translation and expedite the advancement of high-impact projects. After inviting expressions of interest in April, a selection committee…
Additional Patient Response in Pancreatic Cancer Trial
Posted: 6 August 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that a fourth patient enrolled in the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer…
Life-Saving Medical Discovery Centre Hits Major Milestone
Posted: 6 August 2024 The Allan Labor Government is cementing Victoria’s reputation as a global leader in medical research, with Melbourne’s new world-class medical research centre now one step closer to making life-saving scientific discoveries for generations to…
Helping Victoria’s Emerging Researchers Make Their Mark
Posted: 6 August 2024 The Allan Labor Government is backing Victoria’s talented medical researchers to pursue projects that save lives. Minister for Medical Research Ben Carroll today announced that applications are now open for the Labor Government’s Fostering Achievement…
